share_log

Novartis AG Says Novartis Cosentyx Gains Positive CHMP Opinion For Hidradenitis Suppurativa; Opinion Paves Way For First New Treatment Option In Hidradenitis Suppurativa In Nearly A Decade; Regulatory Decision From U.S. FDA Expected Later This Year

Benzinga ·  Apr 27, 2023 23:15
Novartis AG Says Novartis Cosentyx Gains Positive CHMP Opinion For Hidradenitis Suppurativa; Opinion Paves Way For First New Treatment Option In Hidradenitis Suppurativa In Nearly A Decade; Regulatory Decision From U.S. FDA Expected Later This Year
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment